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Abstract The different murine D2-type dopamine receptors
(D2L, D2S, D3L, D3S, and D4) were expressed in Xenopus laevis
oocytes. The D2-type receptors were all similarly and efficiently
expressed in Xenopus oocytes and were shown to bind the D2
antagonist [125I]sulpride. They were all shown to activate Cl3
influx upon agonist stimulation. Using the diagnostic inhibitor
bumetanide, we were able to separate the Na+/K+/2Cl3
cotransporter component of the Cl3 influx from the total
unidirectional Cl3 influx. The D3L subtype was found to operate
exclusively through the bumetanide-insensitive Cl3 influx
whereas the other D2-type receptors acted on the Na+/K+/2Cl3
cotransporter as well. The pertussis toxin sensitivity of the
receptor-activated chloride influx via the Na+/K+/2Cl3 cotrans-
porter varied between the various D2-type receptors showing that
they may couple to different G proteins, and activate different
second messenger systems.
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1. Introduction
Two types of dopamine receptor, named D1 and D2, have
for many years been known to transmit the action of the CNS
neurotransmitter dopamine. These two classes of dopamine
receptors belong to the G protein-linked receptor superfamily,
and di¡er in their pharmacological and biochemical properties
(reviewed in [1,2]). A multiplicity of dopaminergic receptors
have recently been revealed by cloning studies. Each receptor
arises from a di¡erent gene, but still adheres to the original
D1/D2 classi¢cation. Thus, D1-like features are exhibited by
the cloned D1 and D5 receptors, while the D2, D3 and D4
receptors all display D2-like properties [3]. The D2 and D3
receptor subtypes have furthermore been found to be alterna-
tively spliced in the coding region, yielding functional short
and long receptor isoforms [4^8]. These splice variants di¡er
by a stretch of amino acids (29 for the D2 receptor, 21 for the
D3 receptor) located in the putative third cytoplasmic loop.
These stretches of amino acids are either present or absent in
the alternatively spliced isoforms thereby giving rise to the D2
and D3 ‘long’ and ‘short’ subtypes accordingly (D2L, D2S, D3L
and D3S).
The cloned D2, D3 and D4 receptors have been expressed in
various cell lines, and functional studies have revealed their
ability to couple to a range of second messenger pathways [9^
11]. Amino acid sequence comparison shows these three re-
ceptors to be most diverse in their third cytoplasmic domains,
the region highlighted for its role in G protein coupling and
second messenger activation. In addition, for both the D2 and
D3 receptors, alternative splicing occurs in this domain. This
has led to much speculation as to whether the functional
di¡erences between the various dopamine receptors may lie
in their G protein speci¢city and, hence, signal transduction
pathways.
We have previously cloned and sequenced the murine D2,
D3 and D4 receptors [6,12]. In this study, we have expressed
these cloned murine receptors in Xenopus laevis oocytes in
order to examine and compare some of the functional char-
acteristics of the D2L, D2S, D3L, D3S and D4 receptors. The
oocyte of Xenopus laevis represents a powerful tool for study-
ing many of the functions of cells using microinjection of
foreign mRNAs [13] and cDNAs [14].
In the oocyte, most of the Cl3 transport is mediated by the
Cl3 channels (which are directly activated by Ca2) and the
bumetanide-sensitive Na/K/2Cl3 cotransporter, regulated
by protein kinase C (PKC) and protein kinase A (PKA)
[15]. Since the Na/K/2Cl3 cotransporter is regulated by
PKA, activation or inhibition of adenylate cyclase will a¡ect
the Na/K/2Cl3 cotransporter, but not the Cl3 channels.
Presented here is a functional assay for receptors linked via
G proteins to the signal transduction pathways involving
cAMP. The assay, which utilizes the unidirectional Cl3 in£ux
mediated by the endogenous Na/K/2Cl3 cotransporter as a
reporter for functional receptors, is used to demonstrate that
the various D2-type receptors modulate di¡erentially chloride
in£ux following expression in Xenopus laevis oocytes. This
may further support the notion that functional diversity of
dopamine receptors is also a consequence of the signal trans-
duction pathway that they stimulate.
2. Materials and methods
2.1. Materials
All reagents were of analytical grade, and were purchased from
Sigma, St. Louis, MO, unless otherwise stated. Bumetanide was added
to the oocytes from a 7.5 mM stock solution in ethanol. Dopamine
was prepared fresh as a stock solution of 100 mM in a Ca2 free
modi¢ed frog Ringer’s solution (ORi: 107 mM NaCl, 2.5 mM KCl,
1 mM CaCl2, 1 mM MgCl2, 1 mM Na2HPO4, 5 mM HEPES, pH 7.6)
supplemented with penicillin G (10 units/l) and streptomycin sul-
fate (10 mg/l) with 1% ascorbic acid. 36Cl, [125I]sulpride and
[35S]methionine were obtained from Amersham, UK.
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2.2. Frogs and oocytes
Ovarian lobes were surgically removed from Xenopus laevis anes-
thetized with 3-aminobenzoic acid ethyl ester (0.1%). The ovaries were
disrupted into small clumps and oocytes released by incubation with
vigorous agitation at room temperature for 2 h with collagenase (type
IA; 2 mg/ml) in a Ca2 free ORi. Complete release of follicular cells
required subsequent incubation for 10 min in Ca2 free ORi. Defollic-
ulated oocytes of oogenesis stages V and VI were manually selected
and placed in 3 ml Petri dishes (Nunclon, Denmark). The following
day the oocytes were injected with cDNA encoding the D2L, D2S, D3L,
D3S and D4 receptors inserted into the eukaryotic expression vector
pcDNAI/Amp (InVitrogen). The cDNAs were dissolved in H2O, ¢nal
concentration of cDNA was 0.20 ng/nl, and a volume of 9.2 nl was
injected per oocyte. Injections were performed as described by Col-
man [14]. Oocytes were maintained for 3 days at 19‡C in ORi supple-
mented with penicillin G (10 mg/l) and streptomycin sulfate (10 mg/l)
and the medium was changed daily.
2.3. Antibody preparation
The D2-speci¢c antibody directed against peptide SPPERTRY-
SPIPPS corresponding to residues 288^301 of the murine D2 dopa-
mine receptor was elicited and puri¢ed as described previously [16].
2.4. [35S]Methionine labeling and immunoprecipitation
Eight oocytes injected with D2S or D2L cDNAs were labeled for 3 h
at 21‡C, in the presence of 220 WCi of [35S]methionine in 1 ml ORi.
The oocytes were manually homogenized in 65 mM Tris-HCl pH 7.5,
1 mM sodium vanadate and 10 mM EDTA, in the presence of the
protease inhibitors phenylmethylsulfonyl £uoride (PMSF; 1 mM),
leupeptin (5 Wg/ml), soybean trypsin inhibitor (5 Wg/ml) and benzami-
dine (15 Wg/ml). Yolk proteins were removed by 10 min centrifugation
at 25 000Ug. Extracts were solubilized with 2Uimmunoprecipitation
bu¡er (130 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5% Triton X-100,
100 mM NaH2PO4, 1 mM sodium vanadate, 10 mM EDTA, and
10 mg/ml BSA with the protease inhibitors as mentioned above) for
10 min on ice with intermittent vortexing, and spun for 10 min at
12 000Ug. The supernatants were pre-absorbed to protein A-agarose
(Immobilized rProtein A, Repligen), pre-swollen in solubilization bu¡-
er for 30 min at 4‡C. Antibodies were pre-bound to protein A-agarose
by their incubation for at least 1 h at 4‡C. The solubilized lysates were
incubated with the protein A-agarose-bound antibody overnight at
4‡C, with shaking. When peptide inhibition of the immunoprecipita-
tion was performed, the peptide was included at a ¢nal concentration
of 20 WM. Upon immunoprecipitation, beads were washed 5 times at
4‡C in 50 mM Tris-HCl, pH 8.0, 0.1% SDS, 0.1% Triton X-100, 5 mM
EDTA, supplemented with the above mentioned protease inhibitors,
with decreasing concentrations of NaCl starting at 150 mM. The
adsorbed material was eluted from the beads with sample bu¡er (25
mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 5% L-mercaptoethanol,
0.01% bromophenol blue) at 37‡C for 30 min, and electrophoresed on
SDS-polyacrylamide gels as previously described [16].
2.5. Chloride uptake
36Cl3 was used as tracer. The uptake of 36Cl3 was measured by
incubation of the oocytes in ORi with 1% (w/v) ascorbic acid. The
36Cl3 uptake is linear for at least 2 h (data not shown). The total Cl3
uptake was initiated by the simultaneous addition of 36Cl3 (800.000
Bq/ml) and dopamine (100 WM), and followed for 15 min. The uptake
was terminated by 5 washes in ice-cold Na free stop solution (107
mM N-methyl-D-glucamine Cl3, 2.5 mM KCl, 1 mM CaCl2, 1 mM
MgCl2, 1 mM Na2HPO4, 5 mM HEPES, 100 WM bumetanide, pH
7.6). The bumetanide-insensitive Cl3 uptake was measured in the
presence of 30 WM bumetanide. The bumetanide-sensitive Cl3 in£ux
was then calculated as the di¡erence between the total in£ux and the
bumetanide-insensitive £ux. The oocytes were then transferred in
groups of ¢ve into scintillation vials containing 1 ml of 10% SDS in
0.2 M NaOH, and samples were shaken for 3 h. Radioactivity of the
cell lysates was determined by liquid scintillation counting. The uni-
directional Cl3 in£uxes, from several batches of oocytes, are calcu-
lated from the radioactivity of the cell lysates, and the speci¢c activ-
ities of the incubation medium, and presented as nmol/h/oocyte
(mean þ S.D.) with the number of experiments using di¡erent batches
of oocytes in parentheses.
2.6. [125I]Sulpride binding
cDNA injected oocytes were labeled with [125I]sulpride. Brie£y, oo-
cytes were incubated at 22‡C in ORi containing 1% (w/v) ascorbic
acid, 0.1% (w/v) BSA (fraction V), 0.01% (w/v) cytochrome c and
0.5 nM [125I]sulpride (10^100 mCi/ml) for 90 min, followed by four
rapid washes with this bu¡er (without isotope). The oocytes were
tested under the microscope, and any ruptured oocytes were dis-
charged at this stage. The oocytes were counted in groups of ¢ve.
Aliquots of the ¢nal wash were counted to test the e⁄ciency of the
washing procedure: these never exceeded 20 cpm and were used as
background. Non-speci¢c binding was determined using non-injected
oocytes. The radioactivity of the oocytes was determined by Q-radia-
tion counting (Packard System). The [125I]sulpride binding from sev-
eral batches of oocytes is presented as fmol/oocyte (mean þ S.D.), with
the number of experiments using di¡erent batches of oocytes in pa-
rentheses, calculated from the radioactivity of the oocytes and the
speci¢c activities of [125I]sulpride.
3. Results and discussion
We have employed Xenopus laevis oocytes to express the
various murine D2-like receptors (D2L, D2S, D3L, D3S and
D4) following microinjection of the corresponding cDNAs.
In order to determine the level of expression of each receptor
subtype, oocytes were injected with cDNA encoding the mu-
rine D2L, D2S, D3L, D3S or D4 receptors, and groups of oocytes
for each receptor subtype were taken for binding analysis
using the D2-speci¢c ligand [125I]sulpride. All ¢ve D2 subtypes
exhibited signi¢cant [125I]sulpride binding (Table 1), and this
binding was inhibited when performed in the presence of the
competitive ligand, butaclamol (data not shown). While the
level of expression of each receptor varied slightly from one
batch of oocytes to the other, averages of several experiments
showed that all ¢ve subtypes were expressed at approximately
the same level, with [125I]sulpride binding ranging from 2.44 to
3.16 fmol/oocyte (Table 1).
The expressed receptor could be immunoprecipitated from
injected oocytes as shown in Fig. 1 for the D2S receptor. A
band of 80 kDa is immunoprecipitated with the speci¢c anti-
peptide antibodies, while it is not precipitated in the presence
of the relevant peptide, or in non-injected oocytes. This band
most probably represents the glycosylated form of the recep-
tor [17,18]. The lower heavy band of about 60 kDa, which
appears in all lanes, is not speci¢c.
To analyze the function of the expressed receptors, we have
examined and compared second messenger activation between
the respective D2 receptor subtypes. The unidirectional Cl3
in£ux, following dopamine stimulation of D2 receptor-ex-
pressing oocytes, was measured (Table 1). The basal Cl3 in-
£ux in non-injected oocytes is 16.9 þ 2.9 nmol/h/oocyte (n = 6).
This in£ux was increased 5^6-fold upon incubation with dop-
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Fig. 1. Immunoprecipitation of exogenous D2S dopamine receptor
expressed in Xenopus laevis oocytes using the D2-speci¢c anti-pep-
tide antibodies.
B. Skaaning Jensen et al./FEBS Letters 420 (1997) 191^195192
amine, in oocytes expressing the various D2-type dopamine
receptors. All ¢ve dopamine receptor constructs were found
capable of activating a chloride in£ux. While some variation
appeared to exist between the subtypes for the total Cl3 in-
£ux, when these values were normalized to account for di¡er-
ences in receptor number, it was shown that all ¢ve D2-type
receptors produce a similar chloride in£ux after activation by
dopamine (Table 1). Thus, the various dopamine receptors are
similarly expressed in Xenopus oocytes, and are all capable of
acting as functional receptors which activate second messen-
ger pathways upon agonist binding.
The Cl3 in£ux in Xenopus laevis oocytes consists of at least
two components which can be distinguished by the use of
speci¢c ion transport inhibitors, such as the diuretic agent
bumetanide, a speci¢c cotransport inhibitor. Receptors
coupled to changes in chloride in£ux may be operating
through either the Na/K/2Cl3 cotransporter (measured as
the bumetanide-sensitive Cl3 in£ux) and/or the Cl3 channels
(bumetanide-insensitive). The endogenous Cl3 channels which
are directly activated by Ca2 act as an ampli¢cation system
for the increase in intracellular Ca2, thus providing a sensi-
tive, although indirect assay of changes in Ca2 homeostasis.
In order to analyze the relative contribution of each of the
components of the chloride in£ux, and to determine whether
the respective D2-type dopamine receptors may have di¡er-
ential activities at the Na/K/2Cl3 cotransporter, we meas-
ured the agonist-stimulated Cl3 in£ux in dopamine receptor-
expressing oocytes, in the absence or presence of bumetanide
(30 WM). The bumetanide-sensitive Cl3 in£ux contributed by
the cotransporter activity is calculated by subtraction of the
bumetanide-insensitive component from the total Cl3 in£ux.
The two components of the dopamine-induced Cl3 in£ux in
D2-expressing oocytes (the bumetanide-sensitive and -insensi-
tive Cl3 in£ux) are shown in Table 2.
The use of bumetanide revealed some di¡erential properties
in functional activity between the various D2 dopamine re-
ceptor subtypes. While the stimulated Cl3 in£ux in oocytes
expressing the D3L receptor was virtually una¡ected by bume-
tanide, showing that this receptor subtype has no stimulatory
e¡ect on the Na/K/2Cl3 cotransporter, the Cl3 in£uxes in
oocytes expressing the other receptor subtypes were reduced
in the presence of bumetanide. This shows that these receptor
subtypes may act on both the Na/K/2Cl3 cotransporter
and the bumetanide-insensitive Cl3 transport systems.
Although D2 dopamine receptors are thought to operate
through inhibition of adenylate cyclase, they may also inhibit
phospholipase C, leading to reduced PKC activity [19]. Such
reduced PKC activity may lead to activation of the Na/K/
2Cl3 cotransporter as previously suggested [15]. Alternatively,
the cotransporter activity might be explained by activation of
D2 and D4 (but not D3) dopamine receptor by type II adenyl-
ate cyclase, through a release of LQ subunits of the G protein
as reported recently [20].
Concerning the bumetanide-insensitive component of the
Cl3 in£ux, it should be noted that in measuring Cl3 in£ux
in the presence of £ufenamic acid, an inhibitor of Ca2-acti-
vated Cl channels [21], no change in the Cl in£ux in oocytes
expressing either of the dopamine receptors has been observed
(data not shown). This suggests that the bumetanide-insensi-
tive Cl in£ux is not contributed by the Ca2-activated Cl
channel in this expression system. The precise nature of the
bumetanide-insensitive Cl3 in£ux needs further investigation.
The variability in second messenger activity between the
receptor subtypes suggest that the various receptors may in-
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Table 2
E¡ect of dopamine on the Na/K/2Cl3 cotransport activity in Xenopus oocytes injected with cDNA encoding the murine D2S, D2L, D3S, D3L
or D4 dopamine receptors
Receptor subtype Cotransporter (nmol/h/oocyte)
(bumet.-sensitive Cl3 in£ux)
Other Cl3 transporter (nmol/h/oocyte)
(bumet.-insensitive Cl3 in£ux)
Inhibition of total Cl3 in£ux by
bumetanide (%)
D2L 25.7 þ 5.0 97.7 þ 29.2 21
D2S 52.4 þ 23.8 62.4 þ 7.8 46
D3L 0.9 þ 0.9 98.1 þ 15.4 1
D3S 53.7 þ 16.4 81.5 þ 25.8 40
D4 38.3 þ 10.7 54.7 þ 9.3 41
Non-injected 4.7 þ 1.4 9.8 þ 2.4 32
Cl3 uptake was measured as described in Section 2, in the absence and presence of bumetanide. The Cl3 in£ux via the Na/K/2Cl3 cotransporter
is calculated as the Cl3 in£ux in the presence of bumetanide subtracted from the Cl3 in£ux in the absence of bumetanide. The Cl3 in£ux via the
Na/K/2Cl3 cotransporter is presented as the bumetanide-sensitive Cl3 in£ux. The bumetanide-insensitive uptake of Cl3 was measured in the
presence of 30 WM bumetanide. The results are presented as the mean þ S.D. from four to six experiments.
Table 1
Sulpride binding sites, dopamine-induced unidirectional Cl3 in£ux and normalization of the dopamine-induced unidirectional Cl3 in£ux in
Xenopus oocytes injected with cDNA encoding the murine D2S, D2L, D3S, D3L or D4 dopamine receptors
Receptor subtype injected [125I]Sulpride binding sites
(fmol/oocyte) (n = 3)
Total Cl3 in£ux
(nmol/h/oocyte) (n = 4^6)
Normalized Cl3 in£ux
(nmol/h/fmol recep) (n = 4^6)
D2L 2.83 þ 0.56 105.6 þ 28.8 25.2 þ 7.1
D2S 3.16 þ 0.44 102.8 þ 20.5 37.1 þ 11.6
D3L 3.09 þ 0.75 77.8 þ 8.7 29.3 þ 6.5
D3S 2.44 þ 0.26 99.0 þ 21.8 28.1 þ 9.7
D4 2.47 þ 0.05 77.7 þ 23.0 32.0 þ 10.1
Non-injected 0.07 þ 0.02 16.9 þ 2.9 ^
Cell surface binding of [125I]sulpride in cDNA-injected or water-injected oocytes and Cl uptake were measured as described in Section 2. The results
are presented as mean þ S.D. from four to six independent experiments. The normalized Cl in£ux is expressed as the total Cl3 in£ux (nmol/h/
oocyte) per [125I]sulpride binding site (fmol/oocyte) in paired experiments after correction for the in£ux in control oocytes.
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teract with di¡erent signal transduction pathways to modulate
the activity of the Na/K/2Cl3 cotransporter. This led us to
examine the G protein association of these dopamine recep-
tor-activated second messenger pathways. One of the principal
advantages of Xenopus oocytes, which makes them an attrac-
tive system for exogenous expression of G protein-coupled
receptors, is the wide range of G proteins they display. Several
pertussis toxin (PTX)-sensitive G proteins have been identi¢ed
in Xenopus oocytes [22], and in a recent report, Quick and
coworkers [23] described the coexistence of two forms of
phospholipase C activated by PTX-sensitive (Go) or PTX-in-
sensitive (Gq) G proteins in the Xenopus oocyte. We therefore
tested whether the murine dopamine receptors expressed in
the oocytes mediate changes in chloride in£ux through cou-
pling with G proteins sensitive or resistant to PTX.
To this end, we examined the e¡ect of overnight incubation
of the oocytes with PTX (0.5 Wg/ml) on the total dopamine-
induced Cl3 in£ux in oocytes expressing the various D2-type
receptors (Fig. 2A), on the Na/K/2Cl3 cotransporter (that
is bumetanide-sensitive; Fig. 2B) and on the Cl3 in£ux that is
bumetanide-insensitive, i.e. measured in the presence of bume-
tanide (Fig. 2C). Using this assay, we have observed some
functional di¡erences between the respective receptor sub-
types, suggesting that the di¡erent receptor subtypes may cou-
ple to di¡erent G proteins to produce their e¡ect on Cl3
in£ux.
In contrast to the D2 and D3 receptor subtypes, D4 receptor
activity was not signi¢cantly altered by the presence of PTX,
suggesting that in Xenopus oocytes it may couple with one or
more PTX-insensitive G proteins to cause changes in Cl3
in£ux. By contrast, in the case of the D2 receptor, PTX re-
duced the total Cl3 in£ux mediated by the D2S isoform by
approximately 67%, and that mediated by the D2L isoform by
approximately 40% (Fig. 2A). However, the activities of the
two components of this ion in£ux, namely the bumetanide-
sensitive Na/K/2Cl3 cotransporter and the bumetanide-in-
sensitive Cl3 in£ux, di¡ered between these two isoforms.
While the bumetanide-insensitive Cl3 in£ux was reduced by
approximately 60% by PTX for the D2L isoform, it was only
slightly reduced for the D2S isoform (Fig. 2C). Thus, the ma-
jority of the inhibitory e¡ect of PTX on the D2S-induced
in£ux was caused by uncoupling from the signalling cascade
that activates the Na/K/2Cl3 cotransporter. On the other
hand, the signal transduction pathway that activates the co-
transporter after stimulation of the D2L receptor remained
relatively una¡ected by PTX (Fig. 2B), indicating that D2S
and D2L couple to di¡erent G proteins when expressed in
Xenopus oocytes. For the D3 receptor, both long and short
isoforms showed a reduction (50^60%) in the presence of
PTX, at the bumetanide-insensitive Cl3 in£ux (Fig. 2C),
whereas for both D3 receptor isoforms, PTX had little or
no e¡ect on the Na/K/2Cl3 cotransporter, indicated by
the bumetanide-sensitive component of the Cl3 in£ux (Fig.
2B).
The D4 receptor-produced changes in the Cl3 in£ux do not
appear to result from activation of PTX-sensitive G proteins
in Xenopus oocytes (Fig. 2C), implying it acts through non-
Gi-like proteins. Besides PTX-insensitive G proteins coupled
to PLC, such as Gq, a number of other PTX-insensitive
G proteins exist, whose second messenger activity is not
known. One or more of these G proteins could be activated
by the D4 receptor, and subsequently modulate the Cl3 in£ux
pathways in the Xenopus oocyte. In addition, we found that
for PTX-treated oocytes expressing the D3L receptor, there
even appeared to be an increase in the Cl3 in£ux via the
Na/K/2Cl3 cotransporter compared to non-PTX-treated
oocytes. This raises the possibility that this subtype may nor-
mally inhibit the Na/K/2Cl3 cotransporter via a pathway
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Fig. 2. E¡ect of pertussis toxin on the dopamine-induced unidirec-
tional Cl3 in£ux in Xenopus oocytes expressing the murine D2-type
dopamine receptors. Following 60 h of incubation, Xenopus oocytes,
microinjected with D2 receptor cDNAs (9.2 nl; 0.2 ng/nl) were
treated for 12 h with pertussis toxin (0.5 Wg/ml). The uptake of Cl3
was measured by incubation of oocytes in ORi with dopamine (100
WM), pertussis toxin (0.5 Wg/ml) and 36Cl3, as described in Section
2 and carried out in the absence of inhibitor to give the total Cl3
in£ux (A), or in the presence of 30 WM bumetanide (C). The Cl3
in£ux via the Na/K/2Cl3 cotransporter (B) is calculated as the
Cl3 in£ux in the presence of bumetanide (C) subtracted from the
Cl3 in£ux in the absence of bumetanide (total Cl3 in£ux, A) and is
presented as the bumetanide-sensitive 36Cl3 in£ux. The results are
presented as the mean þ S.D. from four to six experiments. Signi¢-
cant di¡erences from the appropriate control oocytes (P9 0.05, us-
ing Student’s independent t-test) are marked by an asterisk.
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which involves a PTX-sensitive G protein. In the presence of
PTX, this inhibition would be removed, and the Na/K/
2Cl3 cotransporter activity would appear to increase. Along
these lines it has been recently shown that the rat D4 receptor
inhibits forskolin-stimulated cAMP accumulation via the
PTX-sensitive GKt2 [24]. Furthermore, PKA is involved in
the activation of the Na/K/2Cl3 cotransporter in several
cell types [25,26], so a receptor-induced inhibition of adenylate
cyclase would be consistent with a suppression of the Na/
K/2Cl3 cotransport activity. Another possibility is that D3L
causes activation of protein kinase C, a protein kinase previ-
ously demonstrated to inhibit the Na/K/2Cl3 cotransporter
in Xenopus oocytes [15].
In this paper, we have presented a rapid and reliable assay
for analyzing and comparing properties of related receptors of
the family of D2-type receptors. Using this technique, we have
shown that the members of this subfamily interact with di¡er-
ent G proteins to produce similar e¡ects further down in the
signal transduction pathway. This approach should facilitate
further analysis of the precise elements involved in the signal
transduction pathways of each D2 receptor subtype, and
should provide useful insight into the signaling mechanisms
of dopamine receptors.
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